BR112020004935A8 - Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular - Google Patents
Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celularInfo
- Publication number
- BR112020004935A8 BR112020004935A8 BR112020004935A BR112020004935A BR112020004935A8 BR 112020004935 A8 BR112020004935 A8 BR 112020004935A8 BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A8 BR112020004935 A8 BR 112020004935A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- lysyl
- prevention
- pharmaceutical composition
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 230000012292 cell migration Effects 0.000 title abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 3
- 230000005012 migration Effects 0.000 abstract 3
- 238000013508 migration Methods 0.000 abstract 3
- 102000017737 Lysine-tRNA Ligase Human genes 0.000 abstract 2
- 108010092041 Lysine-tRNA Ligase Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
Abstract
COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO UM ANTICORPO QUE SE KIGA ESPECIFICAMENTE A N-TERMINAL DE LISIL-TRNA SINTETASE COMO PRINCÍPIO ATIVO PARA PREVENÇÃO OU TRATAMENTO DE DOENÇA RELACIONADA COM MIGRAÇÃO CELULAR. A presente invenção refere-se a um novo uso de um anticorpo que se liga especificamente aoN-terminal da lisil-tRNA sintetase e mais particularmente, a uma composição farmacêutica compreendendo um anticorpo que se liga especificamente a um epítopo incluindo a sequência da SEQ ID NO: 117 no domínio N-terminalda lisil-tRNA sintetase (KRS) ou um fragmento funcional do mesmo como um princípio ativo para prevenir e tratar uma doença relacionada à migração de células imunes. Um anticorpo específico para o N-terminal da KRS fornecido pela presente invenção pode regular a migração de células imunes, exibindo assim efeitos muito notáveis na prevenção, alívio e tratamento de doenças relacionadas à migração de células imunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170118917 | 2017-09-15 | ||
PCT/KR2018/010903 WO2019054819A1 (ko) | 2017-09-15 | 2018-09-17 | 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020004935A2 BR112020004935A2 (pt) | 2022-04-19 |
BR112020004935A8 true BR112020004935A8 (pt) | 2022-07-05 |
Family
ID=65723723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020004935A BR112020004935A8 (pt) | 2017-09-15 | 2018-09-17 | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular |
Country Status (10)
Country | Link |
---|---|
US (1) | US11965038B2 (pt) |
EP (1) | EP3682898A4 (pt) |
JP (1) | JP2020534273A (pt) |
KR (1) | KR102163465B1 (pt) |
CN (1) | CN111629752B (pt) |
AU (1) | AU2018332491B2 (pt) |
BR (1) | BR112020004935A8 (pt) |
CA (1) | CA3084461A1 (pt) |
RU (1) | RU2749591C1 (pt) |
WO (1) | WO2019054819A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3058117C (en) | 2017-03-27 | 2023-10-17 | Medicinal Bioconvergence Research Center | Antibody binding specifically to n-terminal region of lysyl-trna synthetase exposed on cell membrane |
AU2018332491B2 (en) * | 2017-09-15 | 2022-04-14 | Zymedi Co., Ltd. | Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease |
EP3882272A4 (en) * | 2018-09-17 | 2022-10-12 | Zymedi Co., Ltd. | ANTIBODIES SPECIFICALLY BINDING TO AN N-TERMINAL DOMAIN OF LYSYL-ARNT SYNTHETASE EXPOSED ON AN EXTRACELLULAR MEMBRANE |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928136D0 (en) * | 1999-11-29 | 2000-01-26 | Rose Marlene L | Organ rejection and associated conditions |
KR100961392B1 (ko) | 2008-04-15 | 2010-06-07 | 이화여자대학교 산학협력단 | 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터 |
RU2465330C1 (ru) * | 2008-08-18 | 2012-10-27 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК |
JP5628807B2 (ja) | 2008-08-18 | 2014-11-19 | ソウル ナショナル ユニバーシティー インダストリー ファウンデーション | リジルtRNA合成酵素の細胞内水準を調節して癌転移又は癌細胞の移動を調節する方法 |
KR101009501B1 (ko) * | 2008-10-10 | 2011-01-18 | 서울대학교산학협력단 | 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물 |
EP2509625B1 (en) * | 2009-12-11 | 2015-01-28 | Atyr Pharma, Inc. | Histidyl trna synthetases for reducing inflammation |
US8962560B2 (en) * | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
JP2017502672A (ja) | 2013-12-30 | 2017-01-26 | メディシナル バイオコンバージェンス リサーチ センター | 抗krsモノクロナル抗体及びこれの用途 |
US11111396B2 (en) | 2014-10-17 | 2021-09-07 | C3 Nano, Inc. | Transparent films with control of light hue using nanoscale colorants |
US10050713B2 (en) | 2015-03-02 | 2018-08-14 | Futurewei Technologies, Inc. | Optical transceiver using duplex media, self-homodyne detection (SHD), coherent detection, and uncooled laser |
KR20180069146A (ko) | 2016-12-14 | 2018-06-25 | 만도헬라일렉트로닉스(주) | 주차 조향 보조 시스템 및 그 제어방법 |
CA3058117C (en) * | 2017-03-27 | 2023-10-17 | Medicinal Bioconvergence Research Center | Antibody binding specifically to n-terminal region of lysyl-trna synthetase exposed on cell membrane |
AU2018332491B2 (en) | 2017-09-15 | 2022-04-14 | Zymedi Co., Ltd. | Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease |
-
2018
- 2018-09-17 AU AU2018332491A patent/AU2018332491B2/en active Active
- 2018-09-17 JP JP2020515025A patent/JP2020534273A/ja active Pending
- 2018-09-17 CN CN201880074372.5A patent/CN111629752B/zh active Active
- 2018-09-17 EP EP18856914.9A patent/EP3682898A4/en active Pending
- 2018-09-17 RU RU2020113539A patent/RU2749591C1/ru active
- 2018-09-17 BR BR112020004935A patent/BR112020004935A8/pt unknown
- 2018-09-17 CA CA3084461A patent/CA3084461A1/en active Pending
- 2018-09-17 US US16/646,240 patent/US11965038B2/en active Active
- 2018-09-17 WO PCT/KR2018/010903 patent/WO2019054819A1/ko unknown
- 2018-09-17 KR KR1020180111060A patent/KR102163465B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP3682898A1 (en) | 2020-07-22 |
AU2018332491B2 (en) | 2022-04-14 |
JP2020534273A (ja) | 2020-11-26 |
KR20190031189A (ko) | 2019-03-25 |
CN111629752B (zh) | 2024-03-29 |
CA3084461A1 (en) | 2019-03-21 |
RU2749591C1 (ru) | 2021-06-15 |
KR102163465B1 (ko) | 2020-10-07 |
BR112020004935A2 (pt) | 2022-04-19 |
WO2019054819A1 (ko) | 2019-03-21 |
EP3682898A4 (en) | 2021-09-29 |
CN111629752A (zh) | 2020-09-04 |
US20210070880A1 (en) | 2021-03-11 |
US11965038B2 (en) | 2024-04-23 |
AU2018332491A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019017329A2 (pt) | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição | |
BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
BR112018002196A2 (pt) | formulação anti-ifnar1 estável | |
BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
BR112018008805A2 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
BR112020004935A8 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
BR112022003589A2 (pt) | Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
DOP2019000250A (es) | Composicion farmaceutica que comprende selexipag | |
BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
BR112016003293A8 (pt) | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: BIOCONTAC CO., LTD. (KR) |
|
B25A | Requested transfer of rights approved |
Owner name: ZYMEDI CO., LTD. (KR) |